Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sengupta, Shomik
BCG+MMC, NCT02948543: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer	Active, not recruiting	3	501	Europe, RoW	Bacillus of Calmette-Guerin (BCG), OncoTICE, ImmuCYST, TheraCys, Mitomycin (MM)	University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Australia	Bladder Cancer	12/24	12/24
ACTRN12619000517178: Feasibility of Water irrigation following resection of bladder tumour	Completed	N/A	30			Monash University , ANZUP trials group	Bladder Cancer
Ischia, Joseph
BCG+MMC, NCT02948543: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer	Active, not recruiting	3	501	Europe, RoW	Bacillus of Calmette-Guerin (BCG), OncoTICE, ImmuCYST, TheraCys, Mitomycin (MM)	University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Australia	Bladder Cancer	12/24	12/24
ACTRN12620000454976: Can intravenous high dose zinc improve clinical outcomes in patients with COVID-19 infection?	Completed	1/2	160			Austin Health, Australian Urologic Cancer Research Trust	COVID-19 infection, Acute respiratory distress syndrome

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sengupta, Shomik
BCG+MMC, NCT02948543: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer	Active, not recruiting	3	501	Europe, RoW	Bacillus of Calmette-Guerin (BCG), OncoTICE, ImmuCYST, TheraCys, Mitomycin (MM)	University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Australia	Bladder Cancer	12/24	12/24
ACTRN12619000517178: Feasibility of Water irrigation following resection of bladder tumour	Completed	N/A	30			Monash University , ANZUP trials group	Bladder Cancer
Ischia, Joseph
BCG+MMC, NCT02948543: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer	Active, not recruiting	3	501	Europe, RoW	Bacillus of Calmette-Guerin (BCG), OncoTICE, ImmuCYST, TheraCys, Mitomycin (MM)	University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Australia	Bladder Cancer	12/24	12/24
ACTRN12620000454976: Can intravenous high dose zinc improve clinical outcomes in patients with COVID-19 infection?	Completed	1/2	160			Austin Health, Australian Urologic Cancer Research Trust	COVID-19 infection, Acute respiratory distress syndrome